– USA, CA – RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced the appointment of Raymond W. Cohen to its Board of Directors.
About Raymond W. Cohen
Raymond W. Cohen is an accredited public company director and accomplished medical technology executive, and has over four decades of industry experience. He was the co-founder and chief executive officer of Axonics, Inc. (Nasdaq: AXNX), a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America, and was acquired by Boston Scientific in 2024 for $3.7 billion. In March 2025, Raymond W. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical-stage company, led the sale of that company to Boston Scientific for $600 million.
Raymond W. Cohen serves on the boards of several innovative healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS), where he is an independent director and chair of the compensation committee; InspireMD (Nasdaq: NSPR) as an independent director, as well as privately-held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. He also serves as a venture partner with Andera Partners and Sherpa Capital Partners.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens, RxSight Light Delivery Device, and accessories, is the first and only commercially available intraocular lens technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery.
For more: https://www.rxsight.com/us
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.